Get the Stockscreener App
10.02
1.57%
-0.16
Corbus Pharmaceuticals Holdings Inc stock is traded at $10.02, with a volume of 273.14K.
It is down -1.57% in the last 24 hours and up +6.48% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$10.18
Open:
$10.15
24h Volume:
273.14K
Relative Volume:
1.41
Market Cap:
$177.72M
Revenue:
$1.54M
Net Income/Loss:
$-78.54M
P/E Ratio:
-1.6761
EPS:
-5.978
Net Cash Flow:
$-64.50M
1W Performance:
+3.19%
1M Performance:
+6.48%
6M Performance:
-38.34%
1Y Performance:
+72.76%
1-Day Range:
$10.00
$10.65
1-Week Range:
$9.50
$10.73
52-Week Range:
$5.73
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
10.02 | 173.82M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals (CRBP) Advances in Obesity Treatment Tria - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone - TipRanks
Corbus completes enrollment in obesity drug trial - Investing.com
Corbus Pharmaceuticals Holdings initiates last patient first visit in CANYON-1 obesity trial with 240 participants - Traders Union
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity - The Manila Times
Corbus Pharmaceuticals (NASDAQ: CRBP) reaches key Phase 1b obesity trial milestone for CRB-913 - Stock Titan
Corbus hits 240-patient milestone for oral obesity drug study - Stock Titan
Behavioral Patterns of CRBP and Institutional Flows - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus reaches FDA agreement on development path for cancer drug CRB-701 - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
Published on: 2026-04-09 22:47:10 - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. secures ASCO 2026 slot for new CRB-701 clinical findings - Traders Union
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer - Sahm
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Sahm
Jefferies reiterates Corbus Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Secures FDA Alignment on Accelerated Approval Path for CRB-701 in Head and Neck and Cervical Cancer 1 - Minichart
Corbus Pharmaceuticals (CRBP) Aligns with FDA on CRB-701 Study P - GuruFocus
Corbus Aligns With FDA on CRB-701 Registrational Path - TipRanks
Corbus Pharmaceuticals Holdings, Inc. secures U.S. FDA alignment on CRB-701 study for HNSCC and cervical cancer - Traders Union
FDA backs Corbus (NASDAQ: CRBP) CRB-701 registrational plans in HNSCC and cervical cancer - Stock Titan
Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in second-line HNSCC and cervical cancer - marketscreener.com
Mizuho raises Corbus Pharmaceuticals stock price target on CRB-701 By Investing.com - Investing.com Canada
(CRBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Corbus Pharmaceuticals (NASDAQ: CRBP) seeks approval to expand equity plan and confirm pay policies - stocktitan.net
Corbus Pharmaceuticals Holdings (3371.SG) stock price, news, quote and history - Yahoo Finance UK
Corbus Pharmaceuticals Holdings, Inc. advances next-gen ADC targeting Nectin-4 in aggressive cancers - Traders Union
Mizuho raises Corbus Pharmaceuticals stock price target on updated CRB-701 assumptions - Investing.com Canada
CRBP PE Ratio & Valuation, Is CRBP Overvalued - Intellectia AI
CEO Change: What is the cash position of Corbus Pharmaceuticals Holdings Inc2026 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Published on: 2026-03-31 10:02:36 - baoquankhu1.vn
Aug Shorts: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveWeekly Trend Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
STU:3371 PB Ratio: 1.04 — 73% Below Median - gurufocus.com
CRBP SEC FilingsCorbus Pharmaceu 10-K, 10-Q, 8-K Forms - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf to sell equity, debt - Stock Titan
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Corbus Pharmaceuticals Holdings Repeat Insider Selling Not A Positive Indicator - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit - Traders Union
[EFFECT] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
How (CRBP) Movements Inform Risk Allocation Models - Stock Traders Daily
If You Invested $1,000 in Corbus Pharmaceu (CRBP) - Stock Titan
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):